الفهرس 
Methods of Induced Mid-trimester AbortionOnly 14 pages are availabe for public view
 |  | from | 123 |  |  |
| | | from | 123 | | |
Abstract
This randomized controlled study was conducted at Ain Shams University Maternity Hospital, the study included 132 women at reproductive age who were admitted for pregnancy interruption for severe fetal anomaly or IUFD at gestational age between 14-24 weeks.
The aim of this study was to assess the efficacy of carbetocin in preventing placental retention and decreasing blood loss after 2nd trimesteric abortion.
The patients were randomly divided into 2 groups; Group I: it included 66 patients who received intravenous 100 µg Carbetocine after delivery of the fetus.Group II: it included 66 patients who received intravenous infusion 20 IU Oxytocin after delivery of the fetus.
The present study showed that the mean duration of 3rd stage was 33.410 minutes with a standard deviation of ±20.440 in the oxytocin group while in the carbetocin group it was 23.081minutes with a standard deviation of ±16.806 and this difference was statistically significant (p= 0.002).
In this study 8 patients (12.12%) of the oxytocin group had placental retention while in the carbetocin group it was 2 patients (3.03%) and this difference was statistically significant. Apart from these patients who had retention of the placenta (10 patients), all patients had undergone an ultrasound scan to assess the presence of reminants which showed that 8 patients (13.79%) of the oxytocin group had reminants versus 4 patients (6.25%) in the carbetocin group, and this difference was statistically significant.
In this study the mean of blood loss was 106.94 ml with a standard deviation of ±35.23 in the oxytocin group while in the carbetocin group it was 87.18 ml with a standard deviation of ±33.73 and this difference was statistically significant (p= 0.001). None of the patients in the present study needed blood transfusion.
This study showed that in oxytocin group and carbetocin group the patients showed significant increase in the pulse rate but the difference between both groups was non significant statistically. As regards temperature there was no significant change between pre and post treatment value in either groups. As regards blood pressure there was a significant DROP in systolic as well as diastolic in patients of both groups after treatment but the difference between both groups was statistically non significant.
As regards the hematocrit value in the oxytocin group it was lowered significantly after treatment but in the carbetocin group there was no statistically significant difference between its value pre and post treatment, the difference between both groups as regards hematocrit value after treatment was statistically significant.
In this study 41 patients (62.12%) of the oxytocin group and45 (68.18%) of carbetocin group had no adverse effect, 2 patients (3.03%) of the oxytocin group and3 (4.55%) of carbetocin group had vomiting, 7 patients (10.61%) of the oxytocin group and4 (6.06%) of carbetocin group had nausea, 8 patients (12.12%) of the oxytocin group and9 (13.64%) of carbetocin group had headache, 2 patients (3.03%) of each group had backache, 6 patients (9.09%) of the oxytocin group and3 (4.55%) of carbetocin group had abdominal pain, these differences was statistically non significant.